CSIMarket Company Name, Ticker, Competitors, else..
 
Genprex Inc   (GNPX)
Other Ticker:  
 
 
Price: $0.3498 $0.00 -0.029%
Day's High: $0.365 Week Perf: 6 %
Day's Low: $ 0.34 30 Day Perf: -23.96 %
Volume (M): 182 52 Wk High: $ 15.15
Volume (M$): $ 64 52 Wk Avg: $4.66
Open: $0.35 52 Wk Low: $0.28



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Genprex Inc
Genprex Inc is a clinical-stage gene therapy company that focuses on developing revolutionary gene-based treatments for cancer. The company aims to deliver its proprietary gene therapies directly to tumors to unleash the body's natural defense mechanisms against cancer. Genprex's lead product candidate, Oncoprex, is being developed to treat multiple types of cancer, including non-small cell lung cancer. The company is dedicated to improving patient outcomes and revolutionizing cancer treatment through innovative gene therapy solutions.


   Company Address: 3300 Bee Cave Road, #650-227 Austin 78746 TX
   Company Phone Number: 537-7997   Stock Exchange / Ticker: NASDAQ GNPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Genprex Inc

Genprex Inc Shows Improvement in Operating Loss; Analysts Optimistic About Future Success

The Major Pharmaceutical Preparations sector insiders have recently analyzed the first quarter of 2024 results and have observed an operating loss of $-5.996717 million from Genprex Inc. This comes as a concern as the company has not mentioned any revenue during the January to March 31, 2024 financial reporting period. However, it is important to note that the numbers are an improvement from the first quarter of 2023, where the operating loss was $-9.271245 million.
The rising entities in the pharmaceutical industry, such as Genprex Inc, need to efficiently run their operations to reach new levels of success. With the recent financial results, it is evident that the company's business model is unfolding. Genprex Inc also saw some alleviation in the net loss compared to the previous year. In the fiscal span ending the first quarter of 2024, the loss was $-5.969 million, compared to $-9.203 million in the first quarter of 2023.
Genprex Inc

Genprex Inc Makes Strides in Financial Growth, Reports Operating Deficit Improvement in Q4 2023

As an analyst here at the , I have been closely following the financial results of Genprex Inc during the fourth quarter of 2023. While there haven't been any major changes at the company, there are some notable developments that shareholders should pay attention to.
One key aspect is Genprex's operating deficit, which came in at $-5.982254 million during the October to December 31 period. This represents an improvement from the previous quarter, where the operating deficit was $-6.821632 million. It is certainly encouraging to see the company managing to compete more economically.
Stock Offering

Genprex Secures $6.5 Million in Funding to Advance Cancer and Diabetes Therapies

Published Fri, Mar 22 2024 8:10 PM UTC

Genprex Secures $6.5 Million in Funding Through Registered Direct Offering
Genprex, a leading gene therapy company, recently announced the closing of a $6.5 million registered direct offering priced at-the-market under Nasdaq rules. This funding will allow the company to further advance its clinical-stage therapies for patients with cancer and diabetes. With 57.805639 m...
Genprex Inc

Genprex Inc Shines with Impressive Third Quarter 2023 Performance, Outshining Competitors


After the bellwethers in the Major Pharmaceutical Preparations sector, investors have turned their attention towards some lesser-known companies, including Genprex Inc, as they release their earnings reports. The company recently announced an operating shortfall of $-7.786327 million for the third quarter of 2023, triggering concerns among shareholders who eagerly await additional revenue sources.
While it may be tempting to solely focus on the financial figures, it is essential to consider the broader context surrounding Genprex Inc. The company's organizational and operational excellence merits attention, as it is a vital factor in their ability to generate sustainable revenue growth.
As with many growth-focused companies, Genprex Inc may experience some rough patches in pursuit of lucrative revenue sources. The financial period ending September 30, 2023, reflected this, as the deficit expanded to $-7.748 million. However, it is crucial not to overlook the potential opportunities that lie ahead for the company.
Genprex Inc

Genprex Inc Faces Significant Setback in Conduct Amidst Recent Fiscal Period

Investors in the stock market are often on the lookout for positive developments and improvements in the companies they support. However, sometimes unexpected challenges arise, causing concern among stockholders. This has been the case for Genprex Inc during the April to June 2023 reporting season.
Stockholders were not optimistic about any major changes in the company's financial performance during this period. However, they were disheartened to see a significant operating shortfall of $-8.035744 million during the same time frame. While it is difficult news to swallow, it is essential to evaluate the company's recent financial performance objectively.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com